Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Table 4 Best overall response in the as-treated population

Response, n (%)	Q3W (mg/kg)					Q2W (mg/kg)		QW x 2 (mg/kg)	QW x 4 (mg/kg)	Total
Response, n (%)	Cohort 1 0.1 n = 5 (%)	Cohort 2 0.5 n = 5 (%)	Cohort 3 2.5 n = 3 (%)	Cohort 4 10 n = 6 (%)	Cohort 5 20 n = 9 (%)	Cohort 6 10 n = 4 (%)	Cohort 7 20 n = 18 (%)	Cohort 8 20 n = 3 (%)	Cohort 9 20 n = 5 (%)	N = 58 (%)
Objective response	0	0	0	1 (17)	3 (33)	1 (25)	3 (17)	0	0	8 (14)
CR	0	0	0	0	1 (11)^b	0	0	0	0	1 (2)
PR	0	0	0	1 (17)^c	2 (22)^d	1 (25)^e	3 (17)^b	0	0	7 (12)
SD	0	0	1 (33)	2 (33)	2 (22)	1 (25)	6 (33)	2 (67)	4 (80)	18 (31)
PD	3 (60)	3 (60)	1 (33)	1 (17)	3 (33)	2 (50)	5 (28)	1 (33)	1 (20)	20 (35)
Non-evaluable^a	2 (40)	2 (40)	1 (33)	2 (33)	1 (11)	0	4 (22)	0	0	12 (21)

Abbreviations: CR complete response, PD progressive disease, PR partial response, SD stable disease
^aIncludes patients who discontinued study before first disease assessment and patients for whom not all target lesions were evaluated
^bKidney cancer
^cMelanoma
^dKidney cancer (n = 1), melanoma with BRAF mutation (n = 1)
^eMelanoma with BRAF mutation